[ad_1] With the UK stock market turning red at the moment, plenty of investors are looking at real estate investment trusts (REIT) for sanctuary. But are they really the âsafe havenâ that some believe them to be? Or is it…
[ad_1] “ Dianthus Therapeutics posts wider-than-expected Q4 loss of $1.43/share on collapsing revenue, yet shares surge 21.5% on pipeline optimism. Newsdesk · March 10, 2026 Loss widens sharply. Dianthus Therapeutics, Inc. (DNTH) reported a loss of $1.43 per share for…
[ad_1] On the first trading day of February, £1,000 bought roughly 900 shares in Lloyds (LSE: LLOY). Today however, that same £1,000 buys 1,013 shares (ignoring trading commissions) as the bankâs share price has pulled back quite significantly over the…
[ad_1] Esperion Therapeutics, Inc. (ESPR) reported Q4 2025 earnings of $0.22 per share, undershooting analysts’ estimates. The company generated $168.4M in revenue for the quarter. Esperion Therapeutics develops and commercializes non-statin medicines for patients with elevated LDL cholesterol, including its…
[ad_1] International Consolidated Airlines Group (LSE: IAG) shares are having a week! The last seven days have caused a crisis for many an airline, with the skies in or near the Middle East becoming instantly dangerous for travel. Aside for…
[ad_1] Apyx Medical Corporation (APYX), an energy technology company that designs and manufactures electrosurgical equipment and medical devices, reported fourth quarter 2025 financial results. Apyx Medical Corporation (APYX) posted a Q4 2025 loss of $0.03 per share. The company generated…
[ad_1] Billionaire investor Warren Buffett has a brilliantly simple approach to investing. Focus on the underlying business instead of the share price and be greedy when others are fearful. These seem like obvious principles. But itâs surprising how much of…
[ad_1] Protara Therapeutics, Inc. (TARA) posted a Q4 2025 loss of $0.37 per share, narrower than the $0.48 per share loss reported in the year-ago quarter. The clinical-stage biopharmaceutical company continues to advance its lead program TARA-002, an investigational cell…
[ad_1] Barclaysâ (LSE: BARC) shares have experienced a dramatic fall in recent weeks. Currently, the bankâs share price is sitting at 415p â about 18% below the 2026 high set in early February. Is there a buying opportunity to consider…
[ad_1] Ultralife Corp (ULBI) reported a net loss of $0.45 per share for Q4 2025. No consensus estimate was available for comparison. Top-line revenue was $48.5M. Ultralife Corporation designs, manufactures, installs, and maintains power, communication and electronics systems worldwide. The…